Investing.com -- Novo Nordisk (NYSE: NVO) has appointed Maziar Mike Doustdar as its new president and chief executive officer ...

Illinois Gov. JB Pritzker and former U.S. Commerce Secretary Penny Pritzker are at the center of an effort to drive more ...

In India, Zaynich will be positioned as a third-line treatment, primarily for ICU patients when other antibiotics have failed ...

Novo Nordisk (NYSE:NVO) announced on Tuesday that Maziar Mike Doustdar will become its new president and chief executive ...

Novo Nordisk today announced that Maziar Mike Doustdar has been appointed as president and chief executive officer, effective ...

Roland Kolbeck, Ph.D. Appointed as Chief Scientific Officer - - Joe Monahan, Ph.D. will Continue to Support Aclaris as Special Scientific Advisor to the Chief Executive Officer through March 2026 as ...

Professor Robin May is stepping down after completing a five-year term in the role, and will take up a new position as ...

The FDA has cleared investigational new drug applications for ZW251 and RV‑01, advancing novel treatments for solid tumors in first-in-human trials.

Professor Robin May will step down as the FSA’s Chief Scientific Adviser in September to become Interim Chief Scientific ...

NeuroScientific Biopharmaceuticals has made a second heavy-hitting appointment, with Melbourne-based exec Nathan Smith ...

Bagsværd, Denmark, 29 July 2025 - Novo Nordisk today announced that Maziar Mike Doustdar has been appointed as president and chief executive officer, effective 7 August 2025. Mike Doustdar succeeds La ...

Presentation to highlight the Company's proprietary protein-misfolding platform, EpiSelectTM, used to develop PMN310 Posters highlighting PRECISE-AD, the Company's Phase 1b clinical trial design and ...